NRF2 connects Src tyrosine kinase to ferroptosis resistance in glioblastoma
Life Science Alliance · 2024-01 · 7 (1) · e202302205
DOI: 10.26508/lsa.202302205 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, online erschienen am 25.10.2023. Verfasst von Claudia Cirotti und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, University of Rome "Tor Vergata," Rome, Italy claudiacirotti89@gmail.com. Hauptthemen laut MEDLINE: Glioblastoma, Ferroptosis. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione AIRC per la Ricerca sul Cancro ETS, Fondazione Italiana per la Ricerca sul Cancro, Ministero della Salute.
Abstract (Originalsprache)
Glioblastoma is a severe brain tumor characterized by an extremely poor survival rate of patients. Glioblastoma cancer cells escape to standard therapeutic protocols consisting of a combination of ionizing radiation and temozolomide alkylating drugs that trigger DNA damage by rewiring of signaling pathways. In recent years, the up-regulation of factors that counteract ferroptosis has been highlighted as a major driver of cancer resistance to ionizing radiation, although the molecular connection between the activation of oncogenic signaling and the modulation of ferroptosis has not been clarified yet. Here, we provide the first evidence for a molecular connection between the constitutive activation of tyrosine kinases and resistance to ferroptosis. Src tyrosine kinase, a central hub on which deregulated receptor tyrosine kinase signaling converge in cancer, leads to the stabilization and activation of NRF2 pathway, thus promoting resistance to ionizing radiation-induced ferroptosis. These data suggest that the up-regulation of the Src–NRF2 axis may represent a vulnerability for combined strategies that, by targeting ferroptosis resistance, enhance radiation sensitivity in glioblastoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biology, University of Rome "Tor Vergata," Rome, Italy claudiacirotti89@gmail.com.
- Laboratory of Cell Signaling, IRCCS-Fondazione Santa Lucia, Rome, Italy.
- Department of Biology, University of Rome "Tor Vergata," Rome, Italy.
- UOSD Preclinical Models and New Therapeutic Agents Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
- Neuroimmunology Unit, Experimental Neuroscience, IRCCS Fondazione Santa Lucia, Rome, Italy.
- Department of Biology, University of Rome "Tor Vergata," Rome, Italy daniela.barila@uniroma2.it.
ORCID-Profile: Claudia Cirotti, Claudia Contadini, Gerardo Pepe, Marco De Bardi, Giovanna Borsellino, Manuela Helmer-Citterich, Daniela Barilà
Förderung
- Fondazione AIRC per la Ricerca sul Cancro ETS
- Fondazione Italiana per la Ricerca sul Cancro
- Ministero della Salute
- Ministero dell’Università e della Ricerca
Zitieren
APA
Cirotti, C., Taddei, I., Contadini, C., Di Girolamo, C., Pepe, G., De Bardi, M., Borsellino, G., Helmer-Citterich, M., & Barilà, D. (2024). NRF2 connects Src tyrosine kinase to ferroptosis resistance in glioblastoma. Life Science Alliance, 7(1), e202302205. https://doi.org/10.26508/lsa.202302205
Vancouver
Cirotti C, Taddei I, Contadini C, Di Girolamo C, Pepe G, De Bardi M, et al. NRF2 connects Src tyrosine kinase to ferroptosis resistance in glioblastoma. Life Science Alliance. 2024;7(1):e202302205. doi:10.26508/lsa.202302205
BibTeX
@article{Cirotti2024,
author = {Cirotti, Claudia and Taddei, Irene and Contadini, Claudia and Di Girolamo, Claudia and Pepe, Gerardo and De Bardi, Marco and Borsellino, Giovanna and Helmer-Citterich, Manuela and Barilà, Daniela},
title = {NRF2 connects Src tyrosine kinase to ferroptosis resistance in glioblastoma},
journal = {Life Science Alliance},
year = {2024},
volume = {7},
number = {1},
pages = {e202302205},
doi = {10.26508/lsa.202302205}
}
EUVIMED